MiniPlasmid-Pro

Minicircle DNA (mcDNA) is a non-viral, extrachromosomal, covalently closed supercoiled circular gene expression vector. It is derived from conventional plasmids through site-specific recombination technology, which excises the bacterial backbone sequences - including the origin of replication, antibiotic resistance genes, and unmethylated CpG motifs ^[1].

The defining characteristic of mcDNA is the retention of only the eukaryotic expression cassette (comprising the promoter, gene of interest (GOI), and polyadenylation signal), while eliminating the prokaryotic sequences found in conventional plasmids that may contribute to immunogenicity, transgene silencing, or integration risk. This "minimalist" design makes minicircle DNA a safer and more efficacious tool for gene delivery ^[2].

Figure 1 Comparison of conventional plasmid and minicircle (MC) plasmid

In the field of gene therapy and nucleic acid-based medicines, residual parental plasmid (PP) and plasmid backbone (PB) represent critical pain points that drive immunogenic responses and regulatory scrutiny. The MiniPlasmid-Pro system, developed by Zhuhai Shutong Biotechnology, incorporates a deeply engineered streptavidin magnetic bead (SA-Bead) purification platform that elevates minicircle DNA purity to 95% substantially exceeding international regulatory benchmarks.

1. Core Technology: A Paradigm Shift in Magnetic Bead Capture

1.1 Workflow: A 4-Hour Closed-Loop Process from Fermentation to Purification

Figure 2 Comparison of conventional MC plasmid production workflow vs. Shutong MC plasmid production workflow

• Intracellular Recombination and Degradation: L-arabinose induction activates the PhiC31 recombinase and I-SceI endonuclease intracellularly, driving site-directed recombination and initial destruction of the plasmid backbone.

• Magnetic Bead Separation and Recovery: Streptavidin magnetic beads are introduced to physically capture and remove impurities via magnetic force; the resulting supernatant is subjected to ethanol precipitation to yield high-purity MiniPlasmid.

• Efficiency Comparison: Conventional chromatography-based workflows require 48-72 hours, whereas the magnetic bead purification process is completed in just 4 hours, with a stable recovery rate of 94-95%.

2. In-Depth Application Case Study: Advances in Non-Viral Vectors for CAR-T Cell Therapy

Based on the work of Monjezi et al. ^[3], the use of minicircle DNA (MC) to deliver the Sleeping Beauty (SB) transposon system demonstrated remarkable advantages in CAR-T cell manufacturing:

2.1 Markedly Reduced Electroporation Toxicity and Improved Cell Viability

• Low Cytotoxicity: Due to their compact size and absence of bacterial sequences, minicircle plasmids yielded an average post-electroporation T cell survival rate approximately 1.4-fold higher than conventional plasmids for CD19-CAR constructs.

• Yield Advantage: The combination of higher transfection efficiency and lower cytotoxicity resulted in approximately 6-fold greater CD19-CAR T cell expansion over a 14-day culture period compared to conventional plasmid-based methods, without the requirement for antigen-dependent stimulation.

Figure 3 Efficient CAR-T cell manufacturing based on minicircle DNA (MC) and the Sleeping Beauty (SB) transposon system [3]

(a) Schematic of plasmid construction and minicircularization; (b) CAR expression analysis at day 14 post-transfection; (c) Functional assessment and expansion kinetics

2.2 Near-Random Genomic Integration with Enhanced Biosafety

• Safe Harbor Integration: The study demonstrated that 20.8% of MC-derived transposon integrations occurred at genomic "safe harbor" (GSH) loci, compared to only 3% for lentiviral (LV) vectors.

Figure 4 Safety evaluation of integration site distribution for Sleeping Beauty (SB) vs. lentiviral (LV) vectors [3]

• Reduced Oncogenic Risk: Unlike lentiviral vectors, which preferentially integrate near highly expressed or cancer-associated genes, MC-derived vectors showed enrichment in these high-risk regions of only 1.15-1.29-fold, far below the 2.11-2.64-fold enrichment observed for LV vectors.

Figure 5 Comparison of genomic integration characteristics of Sleeping Beauty (SB) and lentiviral (LV) vectors in human T cells [3]

2.3 Durable Long-Term Expression and Functional Consistency

• Expression Stability: MC vectors enabled balanced and durable stable transduction across both CD8⁺ and CD4⁺ T cell subsets.

• Equivalent Efficacy: In a Raji lymphoma xenograft model, CAR-T cells manufactured using the MC-SB system demonstrated tumor eradication capacity and survival benefit equivalent to that achieved with lentiviral methods.

Figure 6 Comparison of genomic integration safety and in vivo antitumor efficacy between the SB transposon system and lentiviral vectors [3]

(a-b) Tumor burden monitoring; (c-d) Effector cell expansion; (e-f) Tumor clearance and survival

3. Broad-Spectrum Applications Across the Industry

Figure 7 Core applications of the MiniPlasmid-Pro platform in gene and cell therapy and nucleic acid-based medicines

Application Scenarios and Solution Advantages

• Gene Replacement Therapy: Eliminates the risk of horizontal transfer of antibiotic resistance genes; well-suited for long-term expression in monogenic disease treatment.

• AR-T / TCR-T Cell Therapy: Enables electroporation-based transfection with reduced cytotoxicity, improving cell viability and transfection efficiency ^[3].

• Viral Vector Manufacturing: Enhances AAV or lentiviral packaging titers while minimizing encapsidation of bacterial backbone sequences during the packaging process.

• mRNA Vaccine Templates: Provides ultra-high-purity linearized templates, reducing upstream generation of impurities such as double-stranded RNA (dsRNA).

• iPSC Reprogramming: Functions as a non-integrating vector, safeguarding genomic integrity throughout the reprogramming process.

4. Upgrade Pathways and Customized Services

Tiered Process Integration Solutions

• Plasmid Engineering: Modifications that preserve existing replication efficiency and transgene expression levels.

• Seamless Process Integration: The magnetic bead purification step is designed to integrate directly into existing alkaline lysis workflows, serving as either an enhancement to or a replacement for conventional purification approaches.

• GMP-Grade Quality Standards: Batch records and Certificates of Analysis (COA) are provided in compliance with ICH Q7A guidelines, encompassing residual quantification by qPCR, mycoplasma testing, and purity analysis by HPLC.

5. Deliverables and Timelines

• High-Purity Product: Delivery of MiniPlasmid with purity >95%.

• Comprehensive Technical Documentation: Includes MC plasmid sequence information, raw qPCR impurity detection data, and stability validation reports.

• Plasmid Construction: 2-3 weeks

• Production and Purification: 1-2 weeks

• Total Delivery Timeline: 4-5 weeks

6. Technical Consultation and Collaboration

Building upon our established MiniPlasmid technology, GeneRulor has successfully integrated an enhanced magnetic bead purification process to deliver minicircle DNA solutions with superior purity, improved safety, and reduced cost. Our team of experienced molecular biology experts is dedicated to advancing the clinical application of ultra-high-purity MC technology across gene therapy, vaccine development, and related fields.

We recognize the unique requirements of each project and offer flexible partnership models, from one-time service engagements to long-term strategic collaborations. Whether you are in early-stage research or preparing to enter clinical trials, we are equipped to provide the technical support and product solutions your program demands. We look forward to partnering with you to drive the advancement of precision medicine.

References

[1] MiniVec: A miniaturized plasmid backbone supporting antibiotic-free and additive-free fermentation with enhanced yield and functionality [Preprint]. (2025). bioRxiv.

[2] Chen, Z. Y., He, C. Y., Ehrhardt, A., & Kay, M. A. (2003). Minicircle DNA vectors devoid of bacterial DNA result in persistent and high-level transgene expression in vivo. Molecular Therapy, 8(5), 495-500.

[3] Monjezi, R., et al. (2017). Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors. Leukemia, 31(1), 186-194.